Risk Stratification in Multiple Myeloma
- PMID: 26883334
- DOI: 10.1007/s11899-016-0307-4
Risk Stratification in Multiple Myeloma
Abstract
There are many prognostic variables in multiple myeloma and the difficulty is in deciding which is truly significant. The widely used International Staging System (ISS) does not incorporate genetics, age, and other important variables in its risk stratification. Although it has its own limitations, the recently published Revised International Staging System (R-ISS) that was built upon the framework of ISS, is a more comprehensive and predictive tool for multiple myeloma patients and should be henceforth utilised. We will review the current prognostic variables and their significance in this paper.
Keywords: Chromosomal Abnormalities; International Staging System; Multiple Myeloma; Risk.
Similar articles
-
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220069 Free PMC article.
-
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27. Haematologica. 2017. PMID: 27789676 Free PMC article.
-
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605179
-
Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80. doi: 10.1016/j.beha.2007.10.002. Best Pract Res Clin Haematol. 2007. PMID: 18070712 Review.
-
Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients.Surg Oncol. 2018 Jun;27(2):321-326. doi: 10.1016/j.suronc.2018.05.005. Epub 2018 May 3. Surg Oncol. 2018. PMID: 29937188 Review.
Cited by
-
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Exp Ther Med. 2016 Aug;12(2):771-776. doi: 10.3892/etm.2016.3401. Epub 2016 May 26. Exp Ther Med. 2016. PMID: 27446274 Free PMC article.
-
Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients.Front Cell Dev Biol. 2020 Dec 3;8:596777. doi: 10.3389/fcell.2020.596777. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33344452 Free PMC article.
-
Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.J Clin Med. 2023 Sep 22;12(19):6132. doi: 10.3390/jcm12196132. J Clin Med. 2023. PMID: 37834777 Free PMC article. Review.
-
Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.Turk J Haematol. 2021 Feb 25;38(1):33-40. doi: 10.4274/tjh.galenos.2020.2020.0115. Epub 2020 Jun 16. Turk J Haematol. 2021. PMID: 32539315 Free PMC article.
-
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.Ann Hematol. 2020 May;99(5):1041-1048. doi: 10.1007/s00277-020-03970-2. Epub 2020 Mar 4. Ann Hematol. 2020. PMID: 32130471
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical